The abstract is read at the publisher; the summary is JClub's.
At least 75 covalent drugs have gained regulatory approval, including therapies for KRAS G12C, EGFR L858R, T790M, and BTK, showing broad clinical reach.
- Why it matters: The field is expanding because covalent targeting can succeed where other approaches fail, and its unique interaction requirements are critical for efficacy.
- What they did: This review summarizes progress against key covalent drug targets, highlighting notable approved examples and recently disclosed candidates for KRAS G12D, WRN helicase, and p53 Y220C.
- The result: Emerging molecules targeting KRAS G12D, WRN helicase, and p53 Y220C are expected to be significant achievements if they receive regulatory approval, reinforcing covalent strategy value.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.